Enhanced γ-globin reactivation and sickle cell correction through a repressor-to-activator motif switch in the promoters.

Sickle cell disease (SCD) is caused by the production of an abnormal adult hemoglobin that generates sickle-shaped red blood cells (RBCs). Transplantation of autologous genetically corrected hematopoietic stem/progenitor cells (HSPCs) represents a promising therapy. Persistent fetal hemoglobin expression improves SCD. Here, we engineered the fetal promoters by replacing the BCL11A repressor-binding site (BS) with a TAL1:GATA1 motif recognized by transcriptional activators. We exploited the prime editing nuclease (PEn) that efficiently installed the TAL1:GATA1 motif in K562 cells, outperforming the original PE. Non-homologous end joining (NHEJ) and/or alternative-end joining (alt-EJ) pathway inhibition enhanced precise editing. However, this strategy was poorly efficient in patients' HSPCs. Alternatively, we used CRISPR-Cas9 nuclease to either disrupt the BCL11A BS via NHEJ and/or alt-EJ or to replace it with the TAL1:GATA1 motif via homology-directed repair (HDR) using a donor ssODN template. NHEJ and alt-EJ inhibition improved product purity, reducing insertions and deletions (indels), and achieving superior precise editing efficiency compared to PEn in K562 and HSPCs. HDR-edited HSPCs preserved clonogenic capacity and differentiated into RBCs showing elevated expression and correction of the sickling phenotype. These results indicate that replacing the BCL11A BS with a TAL1:GATA1 motif is a potent strategy for reactivating to treat SCD.KEYWORDSMT: RNA/DNA editing, activator binding site, fetal hemoglobin, gene editing, prime editing, sickle cell disease© 2026 The Authors.